Reuters logo
BRIEF-Incyte Corp provides additional Phase 1 Data from ECHO-202 trial
October 7, 2016 / 8:16 AM / a year ago

BRIEF-Incyte Corp provides additional Phase 1 Data from ECHO-202 trial

Oct 7 (Reuters) - Press Release :

* Additional phase 1 data from ECHO-202 reinforce durability of response in patients with treatment-naive advanced or metastatic melanoma treated with epacadostat in combination with keytruda (pembrolizumab)

* Says epacadostat in combination with pembrolizumab was well tolerated in Phase 1 population Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below